Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Hydromethylthionine mesylate - TauRx Pharmaceuticals

Drug Profile

Hydromethylthionine mesylate - TauRx Pharmaceuticals

Alternative Names: Hydromethylthionine; leuco-methylthioninium; Leuco-methylthioninium-bis(hydromethanesulfonate); LMT-X; LMTM; LMTX; TRx-0237

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TauRx Pharmaceuticals
  • Class Antidementias; Diamines; Mesylates; Phenothiazines; Small molecules
  • Mechanism of Action Synuclein inhibitors; Tau protein inhibitors; TDP-43 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Dementia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease; Dementia
  • No development reported Parkinson's disease
  • Discontinued Progressive supranuclear palsy

Most Recent Events

  • 23 Sep 2021 Biomarkers information updated
  • 19 May 2020 TauRx Therapeutics plans to initiate enrolment to test the dose of hydromethylthionine in a placebo-controlled confirmatory trial for Dementia in early-2021
  • 19 May 2020 Efficacy data from a phase III TRx237 007 trial in Dementia released by TauRx Therapeutics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top